{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:21Z","timestamp":1707524601903},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"DOI":"10.7759\/cureus.28422","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:25:39Z","timestamp":1661505939000},"source":"Crossref","is-referenced-by-count":0,"title":["Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?"],"prefix":"10.7759","author":[{"given":"Patr\u00edcia","family":"Rosinha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Vilaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Helena","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00743-7","article-title":"Insulin therapy in adults with type 1 diabetes mellitus: a narrative review","volume":"11","author":"Jane\u017e A","year":"2020","unstructured":"Jane\u017e A, Guja C, Mitrakou A, et al.. Insulin therapy in adults with type 1 diabetes mellitus: a narrative review. Diabetes Ther. 2020, 11:387-409. 10.1007\/s13300-019-00743-7","journal-title":"Diabetes Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13963","article-title":"The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications","volume":"22","author":"Owens DR","year":"2020","unstructured":"Owens DR, Bolli GB. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes Obes Metab. 2020, 22:743-54. 10.1111\/dom.13963","journal-title":"Diabetes Obes Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00685-0","article-title":"Fast-acting insulin aspart: the rationale for a new mealtime insulin","volume":"10","author":"Evans M","year":"2019","unstructured":"Evans M, Wilkinson M, Giannpolou A. Fast-acting insulin aspart: the rationale for a new mealtime insulin. Diabetes Ther. 2019, 10:1793-800. 10.1007\/s13300-019-00685-0","journal-title":"Diabetes Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1586\/17434440.2016.1109442","article-title":"Moving toward the ideal insulin for insulin pumps","volume":"13","author":"Cengiz E","year":"2016","unstructured":"Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016, 13:57-69. 10.1586\/17434440.2016.1109442","journal-title":"Expert Rev Med Devices"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13798","article-title":"Use of fast-acting insulin aspart in insulin pump therapy in clinical practice","volume":"21","author":"Evans M","year":"2019","unstructured":"Evans M, Ceriello A, Danne T, et al.. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab. 2019, 21:2039-47. 10.1111\/dom.13798","journal-title":"Diabetes Obes Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00834-5","article-title":"Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences","volume":"59","author":"Haahr H","year":"2020","unstructured":"Haahr H, Heise T. Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. Clin Pharmacokinet. 2020, 59:155-72. 10.1007\/s40262-019-00834-5","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0696-8","article-title":"Faster insulin aspart: a new bolus option for diabetes mellitus","volume":"58","author":"Davis A","year":"2019","unstructured":"Davis A, Kuriakose J, Clements JN. Faster insulin aspart: a new bolus option for diabetes mellitus. Clin Pharmacokinet. 2019, 58:421-30. 10.1007\/s40262-018-0696-8","journal-title":"Clin Pharmacokinet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0931-y","article-title":"Pharmacological properties of faster-acting insulin aspart","volume":"17","author":"Biester T","year":"2017","unstructured":"Biester T, Kordonouri O, Danne T. Pharmacological properties of faster-acting insulin aspart. Curr Diab Rep. 2017, 17:101. 10.1007\/s11892-017-0931-y","journal-title":"Curr Diab Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12803","article-title":"Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial","volume":"19","author":"Heise T","year":"2017","unstructured":"Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial. Diabetes Obes Metab. 2017, 19:208-15. 10.1111\/dom.12803","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13610","article-title":"A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5)","volume":"21","author":"Klonoff DC","year":"2019","unstructured":"Klonoff DC, Evans ML, Lane W, et al.. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019, 21:961-7. 10.1111\/dom.13610","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817750166","article-title":"Pump users clamor for faster insulin: is fast-acting insulin aspart ready for them?","volume":"12","author":"Muchmore DB","year":"2018","unstructured":"Muchmore DB. Pump users clamor for faster insulin: is fast-acting insulin aspart ready for them?. J Diabetes Sci Technol. 2018, 12:152-4. 10.1177\/1932296817750166","journal-title":"J Diabetes Sci Technol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.447","article-title":"Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness","volume":"20","author":"Radermecker RP","year":"2004","unstructured":"Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev. 2004, 20:178-88. 10.1002\/dmrr.447","journal-title":"Diabetes Metab Res Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes-2021","volume":"44","year":"2021","unstructured":"6. Glycemic targets. standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:S73-84. 10.2337\/dc21-S006","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0360","article-title":"Impact of fast-acting insulin aspart on glycemic control in patients with type 1 diabetes using intermittent-scanning continuous glucose monitoring within a real-world setting: the GoBolus study","volume":"23","author":"Danne T","year":"2021","unstructured":"Danne T, Axel Schweitzer M, Keuthage W, et al.. Impact of fast-acting insulin aspart on glycemic control in patients with type 1 diabetes using intermittent-scanning continuous glucose monitoring within a real-world setting: the GoBolus study. Diabetes Technol Ther. 2021, 23:203-12. 10.1089\/dia.2020.0360","journal-title":"Diabetes Technol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/109451-faster-insulin-aspart-for-continuous-subcutaneous-insulin-infusion-is-it-worth-it","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:42Z","timestamp":1707508122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/109451-faster-insulin-aspart-for-continuous-subcutaneous-insulin-infusion-is-it-worth-it"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.28422","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}